By Krishna N. Das NEW DELHI (Reuters) - India on Sunday granted emergency approval to Bharat Biotech's COVAXIN but faced questions after taking the st.
India on Sunday granted emergency approval to Bharat Biotech s COVAXIN but faced questions after taking the step without publishing efficacy data for the homegrown coronavirus vaccine
India s approval of homegrown virus vaccine criticised over lack of data
03 Jan 2021 A health official and a volunteer (R) take part in a mock drill for vaccine delivery at a health centre in New Delhi. AFP
India on Sunday granted emergency approval to Bharat Biotech s COVAXIN but faced questions after taking the step without publishing efficacy data for the homegrown coronavirus vaccine.
The news, announced by the drugs controller general of India (DCGI) who did not take questions, was hailed by Prime Minister Narendra Modi and his ministers as a success in India s self-reliance push.
The government also approved the use of a vaccine developed by AstraZeneca and Oxford University, which will be the lead vaccine in India s immunisation programme until other shots are approved.